COMMUNIQUÉS West-GlobeNewswire

electroCore Announces First Quarter 2025 Financial Results
07/05/2025
First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170, [...]
Emergent BioSolutions Reports First Quarter 2025 Financial Results
07/05/2025
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year First Quarter 2025 Gross Margin % of 50% and [...]
Anika to Participate in the Sidoti Virtual Investor Conference
07/05/2025
BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention [...]
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
07/05/2025
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and [...]
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
07/05/2025
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an [...]
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
07/05/2025
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – [...]
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
07/05/2025
Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of [...]
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
07/05/2025
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers [...]
Best Probiotic For Women: Top Strains for Gut Health, Vaginal health & Constipation - Women Over 40,50,60 - Bioma
07/05/2025
Birštonas, May 07, 2025 (GLOBE NEWSWIRE) -- In this health-conscious era, choosing a good probiotic for women is no longer a supplement option—it's a lifestyle choice for women's health, digestion, and well-being; with [...]
The Best Place to Buy SARMs Online and OTC: Top SARM Brand & Company for Muscle Growth & Fat Loss - Safe Legal SARMS for Sale - CrazyBulk
07/05/2025
New York City, May 07, 2025 (GLOBE NEWSWIRE) -- The best place to buy SARMs is presented by CrazyBulk SARMs are the hottest trend in bodybuilding right now. Bodybuilders, weightlifters, and athletes everywhere are [...]
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
07/05/2025
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of [...]
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
07/05/2025
VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria
07/05/2025
-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU) -- BTK inhibition through the SH2 domain results in greater selectivity as [...]
VALNEVA Declaration of shares and voting rights: April 30, 2025
07/05/2025
VALNEVA Declaration of shares and voting rights April 30, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
VALNEVA Déclaration d’actions et de droits de vote : 30 avril 2025
07/05/2025
VALNEVA Déclaration d’actions et de droits de vote 30 avril 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 rue [...]
Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
07/05/2025
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 7 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company [...]
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
07/05/2025
Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva’s single-dose [...]
Valneva fait un point suite à l'annonce de l'agence européenne des médicaments sur l'utilisation d'IXCHIQ® chez les personnes âgées
07/05/2025
Saint Herblain (France), le 07 mai 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) a entamé une revue [...]
Minister of Education announces CPR, AED, and Opioid Overdose Response Training now mandatory part of the provincial curriculum
07/05/2025
Prince Edward Island students now learning how to save lives CHARLOTTETOWN, Prince Edward Island, May 07, 2025 (GLOBE NEWSWIRE) -- The Advanced Coronary Treatment (ACT) Foundation joined the Government of Prince Edward [...]

Pages